The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Curcumin has been reported to display anti-amyloidogenic activity, not only by inhibiting the formation of new Aβ aggregates, but also by disaggregating existing ones. However, the uptake of Curcumin into the brain is severely restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), modified with g7 ligand for BBB crossing. We performed in depth analyses of possible toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro using primary hippocampal cell cultures. Our results show no apparent toxicity of the formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a promising future approach in the treatment of AD.

Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates / Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Masoni, Martina; Keller, Johannes Robin; Ballestrazzi, Antonio; Vandelli, Maria Angela; Tosi, Giovanni; Grabrucker, Andreas M.. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 526:1-2(2017), pp. 413-424. [10.1016/j.ijpharm.2017.05.015]

Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates

RUOZI, Barbara;BELLETTI, Daniela;PEDERZOLI, FRANCESCA;MASONI, MARTINA;KELLER, JOHANNES ROBIN;BALLESTRAZZI, Antonio;VANDELLI, Maria Angela;TOSI, Giovanni;
2017

Abstract

The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Curcumin has been reported to display anti-amyloidogenic activity, not only by inhibiting the formation of new Aβ aggregates, but also by disaggregating existing ones. However, the uptake of Curcumin into the brain is severely restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), modified with g7 ligand for BBB crossing. We performed in depth analyses of possible toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro using primary hippocampal cell cultures. Our results show no apparent toxicity of the formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a promising future approach in the treatment of AD.
8-mag-2017
526
1-2
413
424
Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates / Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Masoni, Martina; Keller, Johannes Robin; Ballestrazzi, Antonio; Vandelli, Maria Angela; Tosi, Giovanni; Grabrucker, Andreas M.. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 526:1-2(2017), pp. 413-424. [10.1016/j.ijpharm.2017.05.015]
Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Masoni, Martina; Keller, JOHANNES ROBIN; Ballestrazzi, Antonio; Vandelli, Maria Angela; Tosi, Giovanni; Grabrucker, Andreas M.
File in questo prodotto:
File Dimensione Formato  
IJP-D-17-00411R1.pdf

accesso aperto

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 3.6 MB
Formato Adobe PDF
3.6 MB Adobe PDF Visualizza/Apri
ruozi2017.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 2.47 MB
Formato Adobe PDF
2.47 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1142358
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 71
social impact